Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocular Therapeutix reports strong Q4 performance and eyes pivotal trials

Ocular Therapeutix delivered a strong performance in Q4 2022, showcasing revenue growth and advancements in key product developments.
While facing financial challenges and the need for strategic partnerships, the company's solid cash position and product pipeline offer opportunities for future growth.
Investors should monitor Ocular Therapeutix's progress in pivotal trials, commercial expansion, and potential alliances to assess its long-term growth prospects.

Ocular Therapeutix progresses on OTX-TKI program and boosts sales

Ocular Therapeutix showcased advancements in its OTX-TKI program and DEXTENZA sales growth, while addressing financial performance.
Positive clinical trial updates and pricing strategy enhancements position the company for future growth.
Challenges include lack of operational spend guidance and uncertainties in study timelines, with opportunities in trial outcomes and market expansion.

Ocular Therapeutix reports record revenue, navigates pivotal trial funding

Ocular Therapeutix (OCUL) achieved record revenue with DEXTENZA and made significant progress in pipeline development.
While facing financial challenges and operational complexities, the company's strategic initiatives and leadership additions position it for future growth.
Advancements in trial designs, FDA interactions, and funding strategies offer avenues for enhancing product development and commercialization.

Ocular Therapeutix reports strong Q3 revenue growth and advances AMD treatment

Ocular Therapeutix's Q3 performance reflects revenue growth driven by DEXTENZA, with a focus on advancing wet AMD treatment through the OTX-TKI program.
While facing challenges in R&D expenses and trial enrollment criteria, the company is well-positioned with funding options and strategic partnerships.
Opportunities lie in expanding DEXTENZA's market presence, achieving pipeline milestones, and leveraging funding avenues for future growth and innovation.

Ocular Therapeutix excels in retinal focus, poised for leadership

Ocular Therapeutix is on a positive trajectory with advancements in key studies and a strong financial position. The company faces competition and regulatory challenges but has the potential to lead in retinal disease treatment with its innovative approach.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter and year ended December 31, 2021, and provided updates on its ophthalmology pipeline. “Ocular has had another strong quarter and a productive year,” said Antony Mattessich, President and Chief Executive Officer. “Our comme

Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results on Monday, February 28, 2022, after the market close. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced its intention to present data at two medical meetings. Data from the Phase 1 Australian-based clinical trial of OTX-TKI, an axitinib intravitreal implant for the treatment of patients with wet age-related macular degeneration (wet AMD) and other retinal d

Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360

Specialist with a technology platform for optimized delivery of drugs for the therapy of eye diseases. Enormous long-term potential due to potential blockbuster candidates with a differentiated mechanism of action.

Ocular Therapeutix: Shaken By Covid, Perfectly Positioned For Long-Term Gains

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022. In addition to the presentation, the management team will host virtual investor meetings. Investors participating in the conference who are inte

Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Ocular Therapeutix Inc (NASDAQ: OCUL) announced topline results from its Phase 2 trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The clinical trial achieved its pre-specified primary endpoint, demonstrating a statistically significant change of bulbar conjunctival hyperemia from baseline to day 15 compared to vehicle hydrogel.

Ocular Therapeutix's Dexamethasone Ophthalmic Insert Meets Primary Goal In Dry Eye Disease Trial

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced positive topline results from its Phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The Phase 2 clinical trial is a U.S.-based, randomized, double-masked, vehicle-controll

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease

Nano-X Imaging

Renalytix AI plc

With valuations under $2 billion at the moment, these stocks have a lot of room to climb.

3 Small-Cap Stocks to Buy Now and Hold for the Long Haul

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following conferences: Jefferies London Healthcare Conference Presentation: Pre-recorded fireside chat will be made available on-demand beginning on Thursday, November 18th at 8:00 AM GMT / 4:00 AM ET 1x1 Meetings: Friday,

Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated a patent held by Mati Therapeutics, Inc. (Mati) relating to a drug delivery system containing dexamethasone. This decision affirms the judgment made in June 2020 by th

Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.

Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q3 2021 Results - Earnings Call Transcript

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 11.54% and 0.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates

Ocular Therapeutix (NASDAQ:OCUL) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

Ocular Therapeutix: Q3 Earnings Insights

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the third quarter of 2021, and provided updates on its ophthalmology pipeline. “The previous four months have been an exceptionally busy time at Ocular,” said Antony Mattessich, President and Chief Executive Officer. “We had a couple

Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the Centers for Medicare and Medicaid Services (CMS) released its final rules for the Outpatient Prospective Payment System (OPPS) and Medicare Physician Fee Schedule (MPFS) for 2022. The OPPS final rule confirms that DEXTENZA will continue to be separatel

Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the American Academy of Optometry (AAOPT) Annual Meeting 2021 being held in Boston, MA November 3 - 6, 2021. “The AAOPT is the largest meeting in optometry and works to maintain and enhance excellence in optometric practice,

Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter financial results on Monday, November 8, 2021, after the market close. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcas

Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Ocular Therapeutix (OCUL) Q3 Earnings Expected to Decline

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting being held November 12 -15, 2021. “We are happy to have a large presence at AAO this year with six poster presentations in five different indications,” said Mic

Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting

Agenus

Atea Pharmaceuticals

Novavax

Biotech stocks that fall hard on bad news can rebound in a flash.

Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?

The company's experimental dry-eye treatment produced some disappointing clinical trial results.

Here's Why Ocular Therapeutix Stock Is Sinking Today

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results from its Phase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). The Phase 2, U.S.-based, randomized, double-masked, multi-center, vehicle-controlled clinical trial of OTX-CSI wa

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint

Amyris

You can pick up small pieces of these great businesses for next to nothing.

3 Great Stocks You Can Buy With $50 Right Now

Axsome Therapeutics

Chemocentryx

These stocks are expected to put up big gains in a short amount of time.

3 Biotech Stocks That Could Rise 90% or More, According to Wall Street

The FDA has approved Ocular Therapeutix Inc's (NASDAQ: OCUL) supplemental application to broaden the Dextenza label. The approval now adds an indication for ocular itching associated with allergic conjunctivitis.

News for Ocular Therapeutix Stock (OCUL)